Get the Stockscreener App
5.30
1.49%
-0.08
After Hours:
5.29
-0.010
-0.19%
Cingulate Inc stock is traded at $5.30, with a volume of 217.42K.
It is down -1.49% in the last 24 hours and up +17.91% over the past month.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
See More
Previous Close:
$5.38
Open:
$5.39
24h Volume:
217.42K
Relative Volume:
0.40
Market Cap:
$71.39M
Revenue:
-
Net Income/Loss:
$-27.71M
P/E Ratio:
-1.2437
EPS:
-4.2615
Net Cash Flow:
$-19.77M
1W Performance:
-0.38%
1M Performance:
+17.91%
6M Performance:
+13.25%
1Y Performance:
+23.83%
1-Day Range:
$5.23
$5.65
1-Week Range:
$5.23
$6.045
52-Week Range:
$3.16
$11.89
Cingulate Inc Stock (CING) Company Profile
Name
Cingulate Inc
Sector
Industry
Phone
(913) 942-2300
Address
1901 W. 47TH PLACE, KANSAS CITY
Compare CING vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
5.30 | 73.68M | 0 | -27.71M | -19.77M | -4.2615 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Dec-22-23 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Stock (CING) Latest News
Cingulate, Inc. Warrant 2021-03.12.26 on Cingulate Financial Disclosures & SEC Filings - TradingView
Why Is CING Stock Jumping Over 4% In Overnight Trading? - Stocktwits
Cingulate Inc.(NasdaqCM: CING) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Cingulate Inc.(NasdaqCM: CING) added to Russell 3000E Growth Benchmark - marketscreener.com
Cingulate Inc.(NasdaqCM: CING) added to Russell Microcap Index - marketscreener.com
Cingulate Inc.(NasdaqCM: CING) added to Russell 3000E Index - marketscreener.com
Cingulate, Inc. Actuals & Estimates (NASDAQ:CING) - TradingView
CING Forecast — Price Target — Prediction for 2027 - TradingView
Cingulate Inc (CINGW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CING Stock Price, Quote & Chart - ChartMill
Cingulate Inc (CINGW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cingulate Inc (CINGW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cingulate Inc (CINGW) Institutional Confidence - TradingKey
Cingulate Inc (CINGW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cingulate Inc (CINGW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cingulate Inc (CING) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cingulate Inc (CING) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cingulate Inc (CING) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cingulate Inc (CING) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cingulate Inc (CING) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cingulate Inc (CING) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cingulate Inc (CING) Institutional Confidence - TradingKey
Cingulate Inc (CING) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cingulate Inc (CING) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cingulate Inc (CINGW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cingulate Inc (CINGW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cingulate Inc (CINGW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301 - markets.businessinsider.com
Cingulate Secures First U.S. Patent for CTx-1301 ADHD Drug, Extending Exclusivity to 2042 - Minichart
Cingulate issued U.S. patent for CTx-1301, exclusivity extended into Dec 2042 - TradingView
US patent extends Cingulate (NASDAQ: CING) CTx-1301 ADHD exclusivity - Stock Titan
Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday - Sahm
Cingulate director Hargroves buys $490,271 of common stock By Investing.com - Investing.com India
CING Q1 2026 Earnings: Wider-than-expected loss as pre-revenue biotech continues pipeline development - newsline.com
Insider Makes Bold Move With Major Cingulate Inc. Stock Purchase - TipRanks
CING Maintained by Ascendiant Capital -- Price Target Lowered to $52 - GuruFocus
Cingulate director Hargroves buys $490,271 of common stock - Investing.com
Cingulate (CING) director-linked LLC buys shares, warrants as options granted - Stock Titan
Cingulate (CING) director reports initial share and warrant holdings - Stock Titan
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (NASDAQ: CING) Following FDA Complete Response Letter - citybuzz -
FDA focuses on manufacturing for Cingulate CTx-1301, not safety - Stock Titan
FDA slaps CRL on Cingulate’s CTx-1301 NDA - The Pharma Letter
Roth MKM Maintains Cingulate(CING.US) With Buy Rating, Maintains Target Price $10 - Moomoo
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301 - AJMC
Biopharma bites: FDA rebuffs Cingulate's ADHD hopeful, plus Contraline's male contraceptive funding - FirstWord Pharma
FDA Issues Complete Response Letter for Cingulate ADHD Drug CTx-1301 - Patient Care Online
FDA rejects Cingulate's application for ADHD medicine - The Business Journals
FDA Sends Complete Response Letter for Cingulate's CTx-1301 | PharmExec - PharmExec.com
FDA Issues CRL for CTx-1301 in ADHD Over CMC Concerns - HCPLive
Cingulate Gets FDA Request for Updates on ADHD Drug Application - Moomoo
Cingulate Inc - Reuters
Cingulate Inc Stock (CING) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cingulate Inc Stock (CING) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Werth Peter J. | Director |
Feb 06 '26 |
Buy |
5.04 |
19,455 |
98,053 |
117,449 |
| Callahan Jennifer L. | SVP and CFO |
Feb 06 '26 |
Buy |
5.04 |
4,864 |
24,515 |
5,059 |
| Schaffer Shane J. | Chief Executive Officer |
Feb 06 '26 |
Buy |
5.04 |
6,809 |
34,317 |
10,175 |
| Brams Matthew | EVP and Chief Medical Officer |
Feb 06 '26 |
Buy |
5.04 |
1,946 |
9,808 |
4,656 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):